Table 3.
Monitoring of patients on antiviral therapy for HBV and HCV infections (adapted from WHO and European guidelines [5–8])
| HBV | HCV | |
|---|---|---|
| Laboratory | ||
| Transaminases | 3-monthly during year 1, 6-monthly thereafter | At treatment start (3 months after the end of therapy) |
| Renal function | 3-monthly during year 1, 6-monthly thereafter | At treatment start and monthly during sofosbuvir treatment if renal dysfunction at baseline |
| Viral load | 3-monthly during year 1, 6–12-monthly thereafter | Before treatment and 3 months after end of therapy (SVR12) |
| Serology | HBsAg yearly | Before treatment |
| Liver imaging | ||
| Transient elastography | Before treatment | Before treatment |
| Every 2 years thereafter | No added value after SVR | |
| Abdominal ultrasound | 6-monthly in individuals with cirrhosis and others at high risk of HCC | 6-monthly in individuals with cirrhosis or with F3 fibrosis + other comorbidities |